PTX-200, previously known as TCN-P (triciribine phosphate monohydrate), is a potent small molecule inhibitor of the AKT pathway, which plays a key role in the development of many cancers, including breast, ovarian cancer as well as hematologic cancers such as Acute Myeloid Leukemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PTX-200 is currently the subject of two proof of concept trials in breast and ovarian cancer that have commenced at prestigious US Cancer Centers. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center/ Albert Einstein College of Medicine in New York, and the Moffitt Cancer Center and Research Institute in Tampa, Florida. A Phase 1b/2 trial of PTX-200 in combination with current standard of care carboplatin is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Moffitt Cancer Center. In addition, a Phase 1b/2 trial evaluating PTX-200 in combination with cytarabine in acute myeloid leukemia is scheduled to begin accrual in mid-2016.